<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809467</url>
  </required_header>
  <id_info>
    <org_study_id>INCMOR 0208-101</org_study_id>
    <nct_id>NCT04809467</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <acronym>topMIND</acronym>
  <official_title>A Phase 1b/2a Basket Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Combination Therapy With the Anti CD19 Monoclonal Antibody Tafasitamab and the PI3Kδ Inhibitor Parsaclisib in Adult Participants With Relapsed/Refractory Non Hodgkin Lymphoma or Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to&#xD;
      evaluate whether tafasitamab and parsaclisib can be safely combined at the recommended Phase&#xD;
      2 dose (RP2D) and dosing regimen that was established for each of the 2 compounds as a&#xD;
      treatment option for adult participants with R/R B-cell malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b : Number of Treatment Emergent Adverse Events</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1b : Incidence of Dose Limiting Toxicities</measure>
    <time_frame>28 Days</time_frame>
    <description>Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol. All DLTs will be assessed for severity by the investigator using CTCAE v5.0 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 2a : Overall Response Rate</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Defined as the percentage of participants experiencing a best response of Complete Response/Complete Metabolic Response (CR/CMR) or Partial Response/Partial Metabolic Response (PR/PMR) according to the Lugano criteria (Cheson et al 2014) for NHL and the iwCLL criteria (Hallek et al 2018) for CLL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter : Cmax of tafasitamab</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Maximum Observed Plasma Concentration of tafasitamab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter : Cmin of tafasitamab</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Minimum Observed Plasma Concentration of tafasitamab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter : Tmax of tafasitamab</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time to reach maximum plasma concentration of tafasitamab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter : AUC(t) of tafasitamab</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Area under the concentration-time curve from time zero to time of tafasitamab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Parameter : Ctrough of tafasitamab</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>C trough concentration of tafasitamab</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>tafasitamab + parsaclisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be assigned to disease specific cohorts based on the histology of their underlying disease.&#xD;
Cohort 1: R/R DLBCL Cohort 2: R/R MCL Cohort 3: R/R FL Cohort 4: R/R MZL Cohort 5: R/R CLL/SLL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tafasitamab</intervention_name>
    <description>tafasitamab will be administered at a protocol defined dose once a week for cycles 1-3 and every other week from cycle 4 until progression.</description>
    <arm_group_label>tafasitamab + parsaclisib</arm_group_label>
    <other_name>INCMOR00208</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>parsaclisib</intervention_name>
    <description>parsaclisib will be administered at protocol defined dose for cycles 1 through disease progression.</description>
    <arm_group_label>tafasitamab + parsaclisib</arm_group_label>
    <other_name>INCB050465</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed R/R B-cell malignancy: DLBCL (THRLBCL, EBV-positive DLBCL of&#xD;
             the elderly, Grade 3b FL, HGBL with MYC and BCL2 and/or BCL6 rearrangements,&#xD;
             transformed lymphoma); MCL ((with cyclin D1 overexpression or t(11;14); FL (Grade 1,&#xD;
             2, 3a); MZL (extranodal, nodal, splenic) ; CLL, or SLL&#xD;
&#xD;
          -  Willingness to undergo biopsy&#xD;
&#xD;
          -  At least 2 prior systemic treatment regimens, including prior treatment with an&#xD;
             anti-CD20 antibody (all cohorts) or prior treatment with a BTK inhibitor (CLL/SLL)&#xD;
&#xD;
          -  Relapsed, progressive, or refractory NHL or CLL&#xD;
&#xD;
          -  For NHL/SLL: Radiographically measurable nodal or extranodal disease (all cohorts&#xD;
             except CLL)&#xD;
&#xD;
          -  ECOG-PS 0 - 2&#xD;
&#xD;
          -  LVEF ≥ 50%&#xD;
&#xD;
          -  Adequate renal, hepatic, bone marrow function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any other histological type of lymphoma&#xD;
&#xD;
          -  Primary or secondary CNS lymphoma&#xD;
&#xD;
          -  Anticancer and/or investigational therapy within the past 30 days or 5 half-lives&#xD;
&#xD;
          -  Autologous SCT within 6 months of C1D1, and allogeneic SCT within 3 months of C1D1&#xD;
&#xD;
          -  Previous treatment with CD19-targeted therapy or PI3K inhibitors&#xD;
&#xD;
          -  Clinically significant cardiac disease&#xD;
&#xD;
          -  Other malignancy within the past 3 years&#xD;
&#xD;
          -  Active graft-versus-host disease&#xD;
&#xD;
          -  Stroke or intracranial hemorrhage within the past 6 months&#xD;
&#xD;
          -  Chronic or current active infectious disease&#xD;
&#xD;
          -  Positive virus serology for HCV, HBV, HIV&#xD;
&#xD;
          -  Currently pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cancer Center For Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Irccs Istituto Nazionale Dei Tumori</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Irrcs Instituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Unviersitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quironsalud Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed or Refractory</keyword>
  <keyword>Leukemia</keyword>
  <keyword>tafasitamab</keyword>
  <keyword>parsaclisib</keyword>
  <keyword>MOR00208</keyword>
  <keyword>INCMOR00208</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.</ipd_time_frame>
    <ipd_access_criteria>Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.incyte.com/our-company/compliance-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

